This page shows the latest Amgevita news and features for those working in and with pharma, biotech and healthcare.
Otezla fits right into Amgen’s existing psoriasis and anti-inflammatory product range, which includes Enbrel (etanercept) and Amgevita, its biosimilar of AbbVie’s Humira (adalimumab) which is approved and already
Otezla slots into Amgen’s existing psoriasis and anti-inflammatory product range, which includes Enbrel (etanercept) and Amgevita, its biosimilar of AbbVie’s Humira (adalimumab) which is approved and already available
Otezla slots nicely into Amgen’s existing psoriasis and anti-inflammatory portfolio, which includes TNF inhibitor Enbrel (etanercept) and Amgevita, its biosimilar of AbbVie’s top-selling TNF blocker Humira (adalimumab). ... Amgevita is approved and
This includes Enbrel (boosted earlier this month by a successful defence of its US patent) and Amgevita, its Humira biosimilar, which is approved and already available in Europe and approved ahead
is doing with Amgevita.
end. Amgen’s copy Amgevita and Samsung and Biogen’s Imraldi both gained full EU approval last year, and have been joined since by Hyrimoz from Novartis’ Sandoz division, Boehringer
More from news
Approximately 2 fully matching, plus 16 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...